<SEC-DOCUMENT>0001415889-25-003295.txt : 20250206
<SEC-HEADER>0001415889-25-003295.hdr.sgml : 20250206
<ACCEPTANCE-DATETIME>20250206191534
ACCESSION NUMBER:		0001415889-25-003295
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250204
FILED AS OF DATE:		20250206
DATE AS OF CHANGE:		20250206

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Posner Christopher
		CENTRAL INDEX KEY:			0001748265
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36279
		FILM NUMBER:		25598788

	MAIL ADDRESS:	
		STREET 1:		C/O CARA THERAPEUTICS, INC.
		STREET 2:		4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL
		CITY:			STAMFORD
		STATE:			CT
		ZIP:			06902

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001346830
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		400 ATLANTIC STREET, SUITE 500
		CITY:			STAMFORD
		STATE:			CT
		ZIP:			06901
		BUSINESS PHONE:		203-406-3700

	MAIL ADDRESS:	
		STREET 1:		400 ATLANTIC STREET, SUITE 500
		CITY:			STAMFORD
		STATE:			CT
		ZIP:			06901

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cara Therapeutics Inc
		DATE OF NAME CHANGE:	20051213
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4-02072025_120231.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-02-04</periodOfReport>

    <issuer>
        <issuerCik>0001346830</issuerCik>
        <issuerName>Cara Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>CARA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001748265</rptOwnerCik>
            <rptOwnerName>Posner Christopher</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CARA THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>400 ATLANTIC STREET, SUITE 500</rptOwnerStreet2>
            <rptOwnerCity>STAMFORD</rptOwnerCity>
            <rptOwnerState>CT</rptOwnerState>
            <rptOwnerZipCode>06901</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>PRESIDENT AND CEO</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-02-04</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>372</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>4.72</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>13692</value>
                    <footnoteId id="F3"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">This sale was effected pursuant to a &quot;sell to cover&quot; arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.</footnote>
        <footnote id="F2">The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.74 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
        <footnote id="F3">The total number of securities reported as beneficially owned following the reported transaction reflects the 1-for-12 reverse stock split that was effected by the Issuer on December 30, 2024.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Darren DeStefano, Attorney-in-Fact</signatureName>
        <signatureDate>2025-02-06</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
